0001121702-21-000029.txt : 20210511 0001121702-21-000029.hdr.sgml : 20210511 20210511161020 ACCESSION NUMBER: 0001121702-21-000029 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: YIELD10 BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001121702 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS PLASTIC PRODUCTS [3080] IRS NUMBER: 043158289 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33133 FILM NUMBER: 21911367 BUSINESS ADDRESS: STREET 1: 19 PRESIDENTIAL WAY STREET 2: SUITE 201 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 617-583-1700 MAIL ADDRESS: STREET 1: 19 PRESIDENTIAL WAY STREET 2: SUITE 201 CITY: WOBURN STATE: MA ZIP: 01801 FORMER COMPANY: FORMER CONFORMED NAME: METABOLIX, INC. DATE OF NAME CHANGE: 20060717 FORMER COMPANY: FORMER CONFORMED NAME: METABOLIX INC DATE OF NAME CHANGE: 20000810 8-K 1 yten-20210511.htm 8-K yten-20210511
0001121702FALSE00011217022021-05-112021-05-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) May 11, 2021
 
YIELD10 BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
001-33133 04-3158289
(Commission File Number) (IRS Employer Identification No.)
 
19 Presidential Way, Woburn, Massachusetts
 01801
(Address of Principal Executive Offices) (Zip Code)
 
(617) 583-1700
(Registrant’s Telephone Number, Including Area Code) 
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stockYTEN
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o





Item 2.02 Results Of Operations and Financial Condition.
 
On May 11, 2021, Yield10 Bioscience, Inc. issued a press release announcing the financial results for three months ended March 31, 2021. A copy of the press release is attached hereto as Exhibit 99.1. This information, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.




Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit  
No. Description
 
Press Release dated May 11, 2021 announcing financial results for the three months ended March 31, 2021




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  YIELD10 BIOSCIENCE, INC.
   
May 11, 2021
By:/s/ Oliver P. Peoples
  Oliver P. Peoples
  President & Chief Executive Officer


EX-99.1 2 exhibit991-ytenx20210512x8k.htm EX-99.1 Document

yield10logoa501a.jpg


Yield10 Bioscience Announces First Quarter 2021 Financial Results
Management will host a conference call today at 4:30 p.m. (ET) to review
financial results and provide a corporate update
WOBURN, Mass. - May 11, 2021 - Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three months ended March 31, 2021.

"We remain solidly on track for progressing our technical and business plans to support a specialty products business based on our Camelina platform," said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. "During 2021, we will scale-up seed production of certain new Camelina varieties as well as evaluate our novel yield traits in multi-site field trials conducted in the U.S. and Canada. We are also creating strong option value for our performance traits discovered using our GRAIN platform by providing access to our novel trait discoveries through research license agreements to leading seed companies by enabling them to evaluate our traits in the major commercial crops.

"We have commenced scale-up of seed production for our new Camelina varieties, a step required for early commercial-scale planting and for producing nutritional oils and meal for sampling to prospective customers. Scale-up of two of our best prototype PHA bioplastic lines is ongoing in parallel with the development of commercial quality PHA bioplastic lines with the goal of increasing PHA content in the seed. We plan to use PHA Camelina seed from this year’s harvest for larger scale field work in 2022 as well as for initial product evaluation. Permitting for field testing of our regulated traits is substantially complete and we expect planting to be completed in the second quarter.

"Under our collaboration with Rothamsted Research, we are well-positioned with an exclusive option to commercialize advanced omega-3 (DHA+EPA) oil technology developed as a sustainable solution for the aquaculture feed market. In the first quarter, the U.S. Patent and Trademark Office granted to Rothamsted the first patent covering the co-production of omega-3 components DHA and EPA in Camelina. We have ramped up our business development efforts on this technology with a focus on the South American market including establishing agreements with a seed service provider for



evaluation of multiple Camelina varieties in Argentina. Planning and business development activities are also underway in Chile aimed at establishing relationships with growers and oilseed crushers as part of our regulatory activities working toward the approval of Camelina oil and meal in aquaculture feed. The Chilean salmon feed industry is our initial target market for the Camelina omega-3 (DHA+EPA) oil product. In 2021, as we chart a regulatory path forward for commercialization of omega-3 oil and meal, Rothamsted will conduct additional development and seed scale-up activities with its lead Camelina line, pending the lifting of certain COVID restrictions in the U.K.

"We also strengthened our balance sheet in early 2021 which we anticipate will support the achievement of milestones and other advancements in the coming quarters as we execute against our core business strategy of utilizing Camelina as a platform crop to produce fuel, food and PHA bioplastic,” said Dr. Peoples.

Recent Accomplishments
Yield10 engaged a leading seed company to perform seed scale-up of three Camelina lines: E3902, a CRISPR edited high oil line; DH12, a doubled haploid elite line; and a disease resistant elite line. Seed scale-up of these lines is expected to enable future planting at the 100-to-1000 acre scale for subsequent larger scale planting and for producing oil and meal for customer sampling.
Yield10 began planting for its 2021 field trial program to evaluate several seed yield and oil content traits. In addition, the Company will conduct field trials and seed scale-up of two PHA containing Camelina lines. Planting is expected to be completed in the second quarter.
In the first quarter, the first U.S. patent (U.S. Patent No. 10,881,631) covering the co-production of the omega-3 fatty acids DHA and EPA in Camelina was granted to Rothamsted Research Ltd.
In April 2021, USDA-APHIS confirmed that new Camelina lines that had been CRISPR edited in the C3007 (BadC) gene are exempt from regulation under 7 CFR part 340. This clearance was obtained by Yield10 under the SECURE Rule, a new regulatory framework in the U.S. for regulating crops. In the first quarter, a U.S. patent (U.S. Patent No. 10,883,113) was granted to the University of Missouri covering modifications to C3007 genes to increase oil content in oilseed crops. Yield10 has an exclusive license to this technology.
COVID-19 Impact on Operations. The Company has implemented business continuity plans to address the COVID-19 pandemic and minimize disruptions to ongoing operations. To date, despite the pandemic, we have been able to move forward with the operational steps required to execute our



2021 field trials in Canada and the United States. However, it is possible that any potential future closures of our research facilities, should they continue for an extended time period, could adversely impact our anticipated time frames for evaluating and/or reporting data from our field trials and other work we plan to accomplish during 2021 and beyond.
FIRST QUARTER 2021 FINANCIAL OVERVIEW
Cash Position
Yield10 Bioscience is managed with an emphasis on cash flow and deploys its financial resources in a disciplined manner to achieve its key strategic objectives.
Yield10 ended the first quarter of 2021 with $22.7 million in unrestricted cash and investments; a net increase of $13.0 million over unrestricted cash and investments of $9.7 million as of December 31, 2020. During the three months ended March 31, 2021, the Company raised $12.7 million, before offering costs of $0.7 million, from an underwritten public offering of 1,040,000 shares of common stock and received additional cash proceeds of $3.9 million from investors who exercised 481,973 warrants issued in the Company's November 2019 securities offering. Net cash used by operating activities during the first quarter of 2021 was $2.6 million compared to $2.3 million used in the first quarter of 2020. The Company continues to estimate total net cash usage during the full year 2021 within a range of $10.0 - $11.0 million.
The Company's present capital resources are expected to fund its planned operations into the first quarter of 2023. Yield10's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing, including public or private equity financing, secured or unsecured debt financing, and receipt of additional government research grants, as well as licensing or other collaborative arrangements.
Operating Results
Grant revenue for the first quarter of 2021 and first quarter of 2020 were consistent at $0.2 million for both periods. Research and development expenses decreased $0.2 million from $1.5 million in the first quarter of 2020 to $1.3 million in the first quarter of 2021. The decrease was primarily the result of reductions in facility related expense stemming from the elimination of excess space in the Company's Woburn, Massachusetts facility. General and administrative expenses remained at $1.4 million during the first quarters of 2021 and 2020.
Yield10 reported a loss from operations of $2.6 million for the first quarter ended March 31, 2021 compared to a loss from operations of $2.7 million for the same quarter of 2020. The Company reported a total net loss after income taxes of $2.6 million, or $0.60 per share, for the three months



ended March 31, 2021, in comparison to a total net loss after income taxes of $3.6 million, or $2.12 per share, for the three months ended March 31, 2020.
Conference Call Information
Yield10 Bioscience management will host a conference call at 4:30 p.m. (ET) today to discuss the first quarter 2021 results. The Company also will provide an update on the business and answer questions from the investor community. A live webcast of the call with slides can be accessed through the Company's website at www.yield10bio.com in the investor relations events section. To participate in the call, dial toll-free 877-709-8150 or 201-689-8354 (international).
To listen to a telephonic replay of the conference call, dial toll-free 877-660-6853 or 201-612-7415 (international) and enter pass code 13718656. The replay will be available until May 25, 2021. In addition, the webcast will be archived on the Company's website in the investor relations events section.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the “Trait Factory”, to develop improved Camelina varieties for the production of proprietary seed products, and to discover high value genetic traits for the agriculture and food industries. Our goals are to efficiently establish a high value seed products business based on developing superior varieties of Camelina for the production of feedstock oils, nutritional oils, and PHA bioplastics, and to license our yield traits to major seed companies for commercialization in major row crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the company, please visit www.yield10bio.com, or follow the Company on Twitter, Facebook and LinkedIn. (YTEN-E)

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, expectations regarding Yield10’s cash position, cash forecasts and runway, expectations related to research and development activities, intellectual property, the expected regulatory path for traits, reproducibility of data from field tests, the timing of completion of additional greenhouse and field test studies, the planting and the outcomes of 2021 field tests and seed scale-up activities, the signing of research licenses and collaborations, including whether the objectives of those collaborations will be met, whether the Company will be able to generate proof points for traits in development and advance business discussions around its Camelina business plan, the potential impact on operations of the COVID-19 pandemic, and value creation as well as the overall progress of Yield10 Bioscience, Inc., constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience’s filings with the Securities and Exchange Commission. Yield10 Bioscience assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.



Contacts:
Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Investor Relations:
Bret Shapiro, (561) 479-8566, brets@coreir.com
Managing Director, CORE IR
Media Inquiries:
Eric Fischgrund, eric@fischtankpr.com
FischTank PR



(FINANCIAL TABLES FOLLOW)




YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(In thousands, except share and per share amounts)
Three Months Ended
March 31,
20212020
Revenue:
Grant revenue$196 $179 
Total revenue196 179 
Expenses:
Research and development1,316 1,460 
General and administrative1,432 1,387 
Total expenses2,748 2,847 
Loss from operations(2,552)(2,668)
Other income (expense):
Change in fair value of warrants— (957)
Other income (expense), net(1)33 
Total other income (expense)(1)(924)
Net loss before income tax expense(2,553)(3,592)
Income tax expense(8)(8)
Net loss$(2,561)$(3,600)
Basic and diluted net loss per share$(0.60)$(2.12)
Number of shares used in per share calculations:
Basic and diluted4,296,129 1,697,125 





YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(In thousands, except share and per share amounts)
March 31,
2021
December 31,
2020
Assets
Current Assets:
Cash and cash equivalents$18,582 $3,423 
Short-term investments3,262 6,279 
Accounts receivable39 86 
Unbilled receivables120 27 
Prepaid expenses and other current assets527 527 
Total current assets22,530 10,342 
Long-term investments886 — 
Restricted cash264 264 
Property and equipment, net968 921 
Right-of-use assets2,625 2,712 
Other assets295 283 
Total assets$27,568 $14,522 
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable$111 $60 
Accrued expenses840 1,297 
Lease liabilities470 457 
Total current liabilities1,421 1,814 
Lease liabilities, net of current portion3,041 3,163 
Other long-term liabilities12 13 
Total liabilities4,474 4,990 
Commitments and contingencies
Stockholders’ Equity:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized, no shares issued or outstanding— — 
Common stock ($0.01 par value per share); 60,000,000 shares authorized at March 31, 2021 and December 31, 2020; 4,865,335 and 3,334,048 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively49 33 
Additional paid-in capital400,865 384,758 
Accumulated other comprehensive loss(159)(159)
Accumulated deficit(377,661)(375,100)
Total stockholders’ equity23,094 9,532 
Total liabilities and stockholders’ equity$27,568 $14,522 





YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
UNAUDITED
(In thousands)
Three Months Ended
   March 31,
 20212020
Cash flows from operating activities
Net loss$(2,561)$(3,600)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization54 48 
Change in fair value of warrants— 957 
Loss on disposal of fixed assets— 206 
Charge for 401(k) company common stock match44 42 
Stock-based compensation324 137 
Non-cash lease expense87 151 
Deferred income tax provision30 
Changes in operating assets and liabilities:
Accounts receivable47 18 
Unbilled receivables(93)(105)
Prepaid expenses and other assets(6)(69)
Accounts payable51 (144)
Accrued expenses(480)259 
Lease liabilities(109)(236)
Other liabilities(1)18 
Net cash used for operating activities(2,637)(2,288)
Cash flows from investing activities
Purchase of property and equipment(101)(42)
Proceeds from sale of property and equipment— 10 
Purchase of investments(869)(503)
Proceeds from the maturity of short-term investments3,000 750 
Net cash provided by investing activities2,030 215 
Cash flows from financing activities
Proceeds from warrants exercised3,856 928 
Proceeds from public offering, net of issuance costs11,993 — 
Taxes paid on employees' behalf related to vesting of stock awards(83)— 
Net cash provided by financing activities15,766 928 
Effect of exchange rate changes on cash, cash equivalents and restricted cash— (55)
Net decrease in cash, cash equivalents and restricted cash15,159 (1,200)
Cash, cash equivalents and restricted cash at beginning of period3,687 5,749 
Cash, cash equivalents and restricted cash at end of period$18,846 $4,549 

EX-101.SCH 3 yten-20210511.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 yten-20210511_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 yten-20210511_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 yten-20210511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 7 yten-20210511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 yield10logoa501a.jpg begin 644 yield10logoa501a.jpg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yten-20210511_htm.xml IDEA: XBRL DOCUMENT 0001121702 2021-05-11 2021-05-11 0001121702 false 8-K 2021-05-11 YIELD10 BIOSCIENCE, INC. DE 001-33133 04-3158289 19 Presidential Way Woburn MA 01801 617 583-1700 false false false false Common stock YTEN NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
May 11, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 11, 2021
Entity Registrant Name YIELD10 BIOSCIENCE, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-33133
Entity Tax Identification Number 04-3158289
Entity Address, Address Line One 19 Presidential Way
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code 617
Local Phone Number 583-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Central Index Key 0001121702
Amendment Flag false
Title of 12(b) Security Common stock
Trading Symbol YTEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://yield10bio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports yten-20210511.htm exhibit991-ytenx20210512x8k.htm yten-20210511.xsd yten-20210511_cal.xml yten-20210511_def.xml yten-20210511_lab.xml yten-20210511_pre.xml http://xbrl.sec.gov/dei/2021 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "yten-20210511.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "yten-20210511_cal.xml" ] }, "definitionLink": { "local": [ "yten-20210511_def.xml" ] }, "inline": { "local": [ "yten-20210511.htm" ] }, "labelLink": { "local": [ "yten-20210511_lab.xml" ] }, "presentationLink": { "local": [ "yten-20210511_pre.xml" ] }, "schema": { "local": [ "yten-20210511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "yten", "nsuri": "http://yield10bio.com/20210511", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20210511.htm", "contextRef": "if55d1cf2798c4212a7e5735e82ebcb72_D20210511-20210511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://yield10bio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20210511.htm", "contextRef": "if55d1cf2798c4212a7e5735e82ebcb72_D20210511-20210511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001121702-21-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001121702-21-000029-xbrl.zip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end